Eli Lilly recently received Food and Drug Administration approval for new indications on two of its drugs, Cyramz and Taltz.
Cyramz's new indication will offer a new treatment option for patients with metastatic non-small cell lung cancer with certain mutations. The FDA has approved Cyramz (ramucirumab injection, 10 mg/ml solution) to treat the condition in combination with erlotinib. Specifically, it can now be used as a first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 mutations.
With this new approval, Cyramza has six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.
Also approved for a new indication was Taltz (ixekizumab injection 80 mg/ml). Thr drug is now indicated to treat active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation. This approval makes Taltz the first IL-17A antagonist to be approved by the FDA for the condition.
Taltz also is approved for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation, active psoriatic arthritis, or active ankylosing spondylitis, and for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.